MediWound Ltd. (MDWD) to Post FY2018 Earnings of ($0.53) Per Share, Oppenheimer Holdings Forecasts
MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at Oppenheimer Holdings issued their FY2018 EPS estimates for MediWound in a research note issued to investors on Tuesday. Oppenheimer Holdings analyst J. Olson forecasts that the firm will post earnings per share of ($0.53) for the year.
MDWD has been the subject of several other research reports. Jefferies Group cut their price target on MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a report on Friday, July 29th. Zacks Investment Research cut MediWound from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Finally, Wells Fargo & Co. assumed coverage on MediWound in a report on Wednesday, August 17th. They issued an “outperform” rating and a $14.00 price target for the company. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $13.63.
MediWound (NASDAQ:MDWD) traded down 5.68% on Thursday, reaching $5.40. The company had a trading volume of 37,162 shares. MediWound has a one year low of $5.10 and a one year high of $10.47. The company has a 50-day moving average of $6.49 and a 200 day moving average of $7.41. The stock’s market cap is $117.99 million.
MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Monday, November 14th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). MediWound had a negative return on equity of 148.23% and a negative net margin of 1,776.06%. The business earned $0.52 million during the quarter, compared to analyst estimates of $0.61 million. During the same quarter in the previous year, the firm posted ($0.17) EPS. The business’s revenue for the quarter was up 420.0% compared to the same quarter last year.
Several institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP bought a new position in shares of MediWound during the third quarter worth about $1,740,000. United Services Automobile Association boosted its position in shares of MediWound by 1.3% in the third quarter. United Services Automobile Association now owns 125,080 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 1,640 shares during the last quarter. Citadel Advisors LLC boosted its position in shares of MediWound by 4.5% in the third quarter. Citadel Advisors LLC now owns 33,622 shares of the biopharmaceutical company’s stock worth $259,000 after buying an additional 1,456 shares during the last quarter. Morgan Stanley boosted its position in shares of MediWound by 91,055.5% in the third quarter. Morgan Stanley now owns 182,311 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 182,111 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in shares of MediWound during the third quarter worth about $116,000. 26.67% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.